Opioid Induced Respiratory Depression Market Analysis

Opioid-Induced Respiratory Depression: Market Dynamics

Over 15 thousand Americans die every year from respiratory depression due to an overdose of opioids. The development of new sophisticated treatments to treat opioid-induced respiratory depression is one of the major areas of research. Currently, there are mainly two approaches developed, one approach is the opioids design with minimal respiratory effect and the other is the use of drugs that stimulate breathing through non-opioidergic pathways. And there are no pharmacological strategies available to prevent respiratory depression without changing opioid analgesia. This opioid-induced respiratory depression field provide great opportunities for researchers and manufacturers and is expected to boost the growth of opioid-induced respiratory depression market.

Opioid-Induced Respiratory Depression market: Overview

The Anesthesia Patient Safety Foundation has convened multidisciplinary conferences in 2006 and 2011, to address the safety issue for the serious patient with opioid-induced respiratory depression. Today, the administration of naloxone is the only treatment for an opioid overdose. Capnograph is an important device to help healthcare providers in initial assessments of patients to measure the management of naloxone therapy. Accurately measurement of the opioid-induced respiratory depression has been a challenge. To consequently measure the safety advantage of a new monitoring protocol or technology is also very difficult. Lack of research and inconsistent taxonomy for opioid-induced respiratory depression may hinder the opioid-induced respiratory depression market.

Opioid-Induced Respiratory Depression market: Region-wise Outlook

The opioid-induced respiratory depression market in North America is expected to show the highest revenue growth and to hold the largest market shares in the global opioid-induced respiratory depression market due to advanced healthcare infrastructure and high healthcare spending. Additionally, high rate of opioid consumption in this region will boost the opioid-induced respiratory depression market, followed by Europe. The opioid-induced respiratory depression market in the Asia-Pacific region is expected to register the moderate growth due to low healthcare facilities and large untreated patient pool. Whereas, Latin America and the Middle East & Africa are expected to show stagnant opioid-induced respiratory depression market growth due to weak healthcare management and facilities.

Opioid-Induced Respiratory Depression market: Key Players

Some of the key players present in global opioid-induced respiratory depression market are Medtronic plc, Smiths Group, Masimo Corporation, Nihon Kohden Corporation, Covidien, GE Healthcare, Welch Allyn, Becton, Dickinson and Company, BioMed Jena GmbH, Hill-Rom, Inc., Natus Medical Incorporated and others.

The report covers exhaustive analysis on:

• Opioid-Induced Respiratory Depression Market Segments
• Opioid-Induced Respiratory Depression Market Dynamics
• Opioid-Induced Respiratory Depression Market Size
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Value Chain

The regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
• Eastern Europe (Poland, Russia)
• The Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
• Japan
• The Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.